Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology

Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) have been shown to correlate negatively with patient survival. Actual CTC counts before and after treatment can be used to aid in the prognosis of patient outcomes. The presence of circulating tumor materials (CTMat) can advertis...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2019-06, Vol.8 (6), p.553
Main Authors: Bailey, Patrick C, Martin, Stuart S
Format: Article
Language:English
Subjects:
Biology
Biopsy
Cancer therapies
circulating tumor cells
CTC
CTC biology
CTC capture technology
CTM
CTMat
DNA methylation
Epithelial Cell Adhesion Molecule - metabolism
Epithelial-Mesenchymal Transition
FDA approval
Humans
Immunomagnetic Separation
liquid biopsy
Lung cancer
Metastases
Metastasis
Neoplasm Recurrence, Local
Neoplasms - diagnosis
Neoplasms - metabolism
Neoplasms - pathology
Neoplastic Cells, Circulating - chemistry
Neoplastic Cells, Circulating - metabolism
Patients
Prostate cancer
Receptor, ErbB-2 - metabolism
Review
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) have been shown to correlate negatively with patient survival. Actual CTC counts before and after treatment can be used to aid in the prognosis of patient outcomes. The presence of circulating tumor materials (CTMat) can advertise the presence of metastasis before clinical presentation, enabling the early detection of relapse. Importantly, emerging evidence is indicating that cancer treatments can actually increase the incidence of CTCs and metastasis in pre-clinical models. Subsequently, the study of CTCs, their biology and function are of vital importance. Emerging technologies for the capture of CTC/CTMs and CTMat are elucidating vitally important biological and functional information that can lead to important alterations in how therapies are administered. This paves the way for the development of a "liquid biopsy" where treatment decisions can be informed by information gleaned from tumor cells and tumor cell debris in the blood.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells8060553